Development of budesonide nanocluster dry powder aerosols: Processing

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3425-3433

  El Gendy, Nashwa ^a,b   Selvam, Parthiban ^a   Soni, Pravin ^d   Berkland, Cory ^a,c  

^a UNIVERSITY OF KANSAS   (United States)

^b Beni Suef University   (Egypt)

^c University of Kansas   (United States)

^d PharMacro   (United States)

Author keywords

Aerosols; Attrition; Budesonide; Formulation; Inhalation; NanoClusters; Nanoparticles; Nanotechnology; Powder technology; Pulmonary drug delivery

Indexed keywords

BUDESONIDE; NANOPARTICLE;

AEROSOL; ARTICLE; DRUG FORMULATION; PARTICLE SIZE;

EID: 84864069253     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23168     Document Type: Article

References (36)

1. Beck-Broichsitter M, Gauss J, Packhaeuser CB, Lahnstein K, Schmehl T, Seeger W, Kissel T, Gessler T. 2009. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm 367(1-2):169-178.
2. Telko MJ, Hickey AJ. 2005. Dry powder inhaler formulation. Respir Care 50(9):1209-1227.
3. Patton JS, Byron PR. 2007. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 6(1):67-74.
4. Henning A, Schneider M, Nafee N, Muijs L, Rytting E, Wang X, Kissel T, Grafahrend D, Klee D, Lehr CM. 2010. Influence of particle size and material properties on mucociliary clearance from the airways. J Aerosol Med Pulm Drug Deliv 23(4):233-241.
5. Rasenack N, Steckel H, Müller BW. 2003. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci 92(1):35-44.
6. Young PM, Chan H, Chiou H, Edge S, Tee THS, Traini D. 2007. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci 96(5):1331-1341.
7. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. 2006. Amorphous drug nanosuspensions, 1. Inhibition of Ostwald ripening. Langmuir 22(3):906-910.
8. Jacobs C, Müller RH. 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19(2):189-194.
9. El-Gendy N, Berkland C. 2009. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 26(7):1752-1763.
10. El-Gendy N, Gorman EM, Munson EJ, Berkland C. 2009. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci 98(8):2731-2746.
11. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. 2009. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 369(1-2):136-143.
12. Shi L, Plumley CJ, Berkland C. 2007. Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir 23(22):10897-10901.
13. Peek LJ, Roberts L, Berkland C. 2008. Poly (d, l-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins. Langmuir 24(17):9775-9783.
14. Kompella UB, Bandi N, Ayalasomayajula SP. 2003. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 44(3):1192-1201.
15. Christensson C, Thoren A, Lindberg B. 2008. Safety of inhaled budesonide: Clinical manifestations of systemic corticosteroid-related adverse effects. Drug Saf 31(11):965-988.
16. Kelly MM, O'Connor TM, Leigh R, Otis J, Gwozd C, Gauvreau GM, Gauldie J, O'Byrne PM. 2010. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J Allergy Clin Immunol 125(2):349-356-e13.
17. Singh S, Amin AV, Loke YK. 2009. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 169(3):219.
18. Brantley SL, Mellott NP. 2000. Surface area and porosity of primary silicate minerals. Am Mineral 85(11-12):1767.
19. Walton KS, Snurr RQ. 2007. Applicability of the BET method for determining surface areas of microporous metal-organic frameworks. J Am Chem Soc 129(27):8552-8556.
20. Sethuraman VV, Hickey AJ. 2002. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech 3(4):7-16.
21. Stobbs B, McAulay E, Bogard H, Monsallier E. 2009. Evaluation of the fast screening impactor (FSI) for determining fine particle fraction of dry powder inhalers. Drug Deliv Lungs 20:158-161.
22. Mitchell JP, Nichols SC. 2011. Summary of abbreviated impactor measurement workshop organized by the European Pharmaceutical Aerosol Group. Ther Deliv 2(3):307-310.
23. Copley M, Director S, Park CQB. 2011. Refining inhaled product testing.Frederick Furness Publishing, Copley Scientific, Nottingham, United Kingdom: 8-10.
24. g. J Pharm Sci 96(5):1398-1407.
25. Trasi NS, Boerrigter SXM, Byrn SR. 2010. Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin. Pharm Res 27(7):1377-1389.
26. Aillon KL, El-Gendy N, McDonald J, Dennis C, Berkland C. 2010. Iodinated NanoClusters as an inhaled CT contrast agent for lung visualization. Mol Pharm 7(4):1274-1282.
27. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. 2010. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate. J Pharm Sci 99(8):3415-3429.
28. Planinsek O, Zadnik J, Kunaver M, Srcic S, Godec A. 2010. Structural evolution of indomethacin particles upon milling: Time-resolved quantification and localization of disordered structure studied by IGC and DSC. J Pharm Sci 99(4):1981-1968.
29. Zimper U, Aaltonen J, McGoverin CM, Gordon KC, Krauel-Goellner K, Rades T. 2010. Quantification of process induced disorder in milled samples using different analytical techniques. Pharmaceutics 2(1):30-49.
30. Fiegel J, Fu J, Hanes J. 2004. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release 96(3):411-423.
31. Frijlink H, De Boer A. 2004. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 1(1):686-687.
32. Vanbever R, Ben-Jebria A, Mintzes JD, Langer R, Edwards DA. 1999. Sustained release of insulin from insoluble inhaled particles. Drug Dev Res 48(4):178-185.
33. Lobo JM, Schiavone H, Palakodaty S, York P, Clark A, Tzannis ST. 2005. SCF-engineered powders for delivery of budesonide from passive DPI devices. J Pharm Sci 94(10):2276-2288.
34. Feddah MR, Brown KF, Gipps EM, Davies NM. 2000. In vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: Influence of inspiratory flow rates. J Pharm Pharm Sci 3(3):318-324.
35. Sahib MN, Darwis Y, Khiang PK, Tan YTF. 2010. Aerodynamic characterization of marketed inhaler dosage forms: High performance liquid chromatography assay method for the determination of budesonide. Afr J Pharm Pharmacol 4(12):878-884.
36. Hirst P, Bacon R, Pitcairn G, Silvasti M, Newman S. 2001. A comparison of the lung deposition of budesonide from Easyhalero, Turbuhaleroand pMDI plus spacer in asthmatic patients. Respir Med 95(9):720-727.